Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

It has been estimated that chronic cough affects up to 10% of the US population, with one in five of them getting no benefit from current treatments such as opioids and corticosteroids.

An occasional cough helps clear irritants and secretions from your lungs and prevents infection. But if you develop a chronic cough that persists for weeks, you should find out if you have a medical ...

Chronic cough remains a persistent challenge for clinicians ... Duffy disclosed consultant relationships with Merck and with Bellus Health (now GSK). Irwin disclosed royalties as a codeveloper ...

GSK expects to launch its RCC drug commercially in 2026. Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two complete response ...